SAS Output

23-FEB-2019 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 Y 1 Lead-in Continuous Dosing 248 241 40 20 11 4 1 09/19/2014 234 98
            241 40 20 11 4 1      
 
    2 Y 2 Continuous Dosing 216 101 19 7 6 2 1 09/19/2014    
        3 Intermittent Dosing   98 20 8 8 4 0      
            199 39 15 14 6 1      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 19 13 5 2 1 1 02/06/2017 90 41
            19 13 5 2 1 1      
 
  S1607-MELAN, Adv, T-VEC, MK-3475 1 Y 1 T-VEC + MK-3475(pembrolizumab) 64 12 12 10 4 1 1 06/05/2018 32 19
            12 12 10 4 1 1      
 
  S1616-MELAN, Adv, Ipilimumab Nivolumab 1 Y 1 Ipilimumab 94 8 6 0 0 0 0 10/23/2017 271 109
        2 Nivolumab + Ipilimumab   22 17 8 4 1 0      
            30 23 8 4 1 0      
 
  S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab 1 Y 1 Adjuvant Arm 556 1 1 1 1 1 0 02/15/2019 135 52
            1 1 1 1 1 0      
 
    2 Y 3 Surgery 556 1 1 1 1 1 1 02/15/2019    
            1 1 1 1 1 1      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   33 9 6 3 3 1 11/03/2015 365 144
            33 9 6 3 3 1      
 
    2 E Total Registrations   12 6 1 0 0 0 11/03/2015    
            12 6 1 0 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   36 0 0 0 0 0 03/25/2016 225 94
            36 0 0 0 0 0      
 

23-FEB-2019 6:10

MELAN Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab 3 Adjuvant Therapy 06-Dec-18